Trial Profile
An open-label, phase I study of BM-ca in indolent B cell Non-Hodgkin's lymphoma patients, refractory to or relapsed after Rituximab treatment.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2012
Price :
$35
*
At a glance
- Drugs BM ca (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- 31 Jul 2012 Actual end date (6 Jul 2012) added as reported by University Hospital Medical Information Network - Japan.
- 06 Jul 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 29 Mar 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.